Comparison of metabolic parameters during treatment for schizophrenia with olanzapine intramuscular long-acting injection versus olanzapine oral formulation

被引：0
作者：
Gulliver, A. [1 ]
McDonnell, D. P. [1 ]
Kryzhanovskaya, L. A. [1 ]
Zhao, F. [1 ]
Detke, H. C. [1 ]
Feldman, P. D. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2008年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [31] Response, remission and relapse during the long-term treatment of schizophrenia patients with long-acting injectable risperidone versus olanzapine
    Potapov, A.
    Eduard, T.
    Sergey, M.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 158 - 158
  • [32] Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
    Ascher-Svanum, Haya
    Montgomery, William S.
    McDonnell, David P.
    Coleman, Kristina A.
    Feldman, Peter D.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2012, 5 : 391 - 398
  • [33] APPROACHES TO FORMULATION OF A LONG-ACTING INTRAMUSCULAR INJECTION
    FLORENCE, AT
    JENKINS, AW
    LOVELESS, AH
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1973, 25 : P120 - P121
  • [34] Effectiveness and tolerability of olanzapine long-acting injection versus first-generation depot for schizophrenia: clinical outcomes
    Parise, V. Fricchione
    Balletta, G.
    Addeo, L.
    Foti, M. G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S477 - S478
  • [35] Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data
    Holland C Detke
    Fangyi Zhao
    Michael M Witte
    BMC Psychiatry, 12
  • [36] Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data
    Detke, Holland C.
    Zhao, Fangyi
    Witte, Michael M.
    BMC PSYCHIATRY, 2012, 12
  • [37] LONG-TERM FUNCTIONAL IMPROVEMENTS IN THE 2-YEAR TREATMENT OF SCHIZOPHRENIA OUTPATIENTS WITH OLANZAPINE LONG-ACTING INJECTION
    Ascher-Svanum, Haya
    Novick, Diego
    Haro, Josep M.
    Bertsch, Jordan
    McDonnell, David
    Detke, Holland
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S165 - S165
  • [38] Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
    Ascher-Svanum, Haya
    Novick, Diego
    Maria Haro, Josep
    Bertsch, Jordan
    McDonnell, David
    Detke, Holland
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 1125 - 1131
  • [39] Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?
    Lukasik-Glebocka, Magdalena
    Sommerfeld, Karina
    Tezyk, Artur
    Panienski, Pawel
    Zaba, Czeslaw
    Zielinska-Psuja, Barbara
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 117 (03) : 213 - 214
  • [40] Comparison of metabolic parameters among patients of schizophrenia on treatment with Olanzapine and Risperidone
    Singh, Archana
    Tomar, Abhay Singh
    Khess, C. R. J.
    Munda, Sanjay
    Siddiqui, Aleem
    Shivani
    INDIAN JOURNAL OF PSYCHIATRY, 2020, 62 : S96 - S96
12345